Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 15 Jul 2021
Another month, another terminated appraisal of a cancer medicine
14 July 2021 - This time it is a medicine for adults and children with acute lymphoblastic leukaemia. ...
Posted by Michael Wonder on 15 Jul 2021
ATAGI update following weekly COVID-19 meeting (14 July 2021)
15 July 2021 - An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their weekly meeting on 14 ...
Posted by Michael Wonder on 15 Jul 2021
Pharma companies fined after 10,000% price rise for life saving drug
15 July 2021 - UK watchdog imposes £260 million in penalties for increases in costs of hydrocortisone tablets. ...
Posted by Michael Wonder on 15 Jul 2021
Cystic fibrosis patients upset over recommended restrictive criteria for life saving drug
15 July 2021 - 'By narrowly defining accessibility and continuation criteria CADTH’s recommendation overlooks many of Trikafta’s significant benefits,' says chief ...
Posted by Michael Wonder on 15 Jul 2021
Biogen Alzheimer's drug hits roadblocks with some hospitals, insurers
15 July 2021 - Biogen's Alzheimer's drug, the first new treatment for the memory-robbing disease in nearly 20 years, hit ...
Posted by Michael Wonder on 15 Jul 2021
Aduhelm may not cure Alzheimer’s, but it might help fix drug prices
17 July 2021 - The controversial drug is so expensive that it has attracted the interest of Congress. ...
Posted by Michael Wonder on 15 Jul 2021
Health economic assessment of Oncotype DX in breast cancer
12 July 2021 - At the request of the regions' medical technology product council, the MTP council, TLV has carried out ...
Posted by Michael Wonder on 15 Jul 2021
Merck’s MET inhibitor tepotinib gains positive opinion from MHRA
15 July 2021 - The UK MHRA has issued a positive scientific opinion for Merck’s tepotinib for the treatment of ...
Posted by Michael Wonder on 15 Jul 2021
COVID-19 vaccine weekly safety report (15 July 2021)
15 July 2021 - Seven additional cases of blood clots with low blood platelets have been assessed as thrombosis with thrombocytopenia ...
Posted by Michael Wonder on 14 Jul 2021
No more sending Kiwis across the ditch as new national neuroendocrine cancer treatment service opens
14 July 2021 - The opening of a new multimillion dollar national service to treat neuroendocrine cancer means patients will ...
Posted by Michael Wonder on 14 Jul 2021
FDA chief tells reporter ‘move on’ when pressed on Biogen Alzheimer’s drug approval
14 July 2021 - Acting FDA Commissioner Dr. Janet Woodcock pushed back against questions from a journalist about the approval of ...
Posted by Michael Wonder on 14 Jul 2021
Patient impact statement: FDA approval of Kerendia to help slow kidney disease and failure associated with type 2 diabetes
14 July 2021 - The American Association of Kidney Patients today issued the following statement regarding the recent approval by the ...
Posted by Michael Wonder on 14 Jul 2021
FDA chief Janet Woodcock acknowledges agency may have misstepped in process leading up to Alzheimer’s drug approval
14 July 2021 - Acting FDA Commissioner Janet Woodcock acknowledged on Wednesday her agency may have misstepped in its handling ...
Posted by Michael Wonder on 14 Jul 2021
NICE feedback?
13 July 2021 - NICE is quite far along a NICE led process to review its methods and processes for ...
Posted by Michael Wonder on 14 Jul 2021
PM speaks about COVID-19, Fiji and PHARMAC funding
14 July 2021 - Prime Minister Jacinda Ardern spoke to media after a speech at the New Zealand Institute of International ...